“SGLT2 Inhibitors in Elderly and Frail CKM Patients Consistent Benefit across Age and Frailty, With No Excess Hypoglycaemia”. 2026. Diabzen 4 (15): 28-29. https://thediabzen.com/index.php/d/article/view/57.